Project Grant P01CA295557
Award Date 8/26/26
Completion Date 7/31/31
Dollars Obligated $2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Bronx, NY 10461, USA
Similar Awards
- The National Institutes of Health National Cancer Institute awarded Albert Einstein College of Medicine $431,970 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to refine and validate an MRI-based imaging technique for detecting tumor microenvironment of metastasis (TMEM) doorways in breast cancer. The award funds development of TMEM doorway activity-MRI (TDAM), a dynamic contrast-enhanced MRI method designed to measure vascular opening events...
- The National Cancer Institute awarded Albert Einstein College of Medicine $687,291 on July 1, 2026, to fund research linking cancer driver mutations to regulatory T cell immunosuppression under the Cancer Biology Research program (CFDA 93.396). The research investigates how oncogenic mutations in aggressive breast tumors directly suppress antitumor immune responses, with particular focus on MLL3 inactivation in combination with PI3KCA activation and P53 inactivation—mutations that collectively...
- The National Cancer Institute awarded Albert Einstein College of Medicine $168,000 on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate dormancy and recurrence mechanisms in pancreatic ductal adenocarcinoma. The research examines how disseminated tumor cells in pancreatic cancer patients enter a dormant state, allowing minimal residual disease to persist after surgery and chemotherapy despite high initial response rates. The project focuses on two...
- The National Institutes of Health National Cancer Institute awarded Albert Einstein College of Medicine $442,187 on July 15, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate how physical constriction influences cancer stem cell induction during metastasis. The research combines fluorescent biosensors for stemness with microfabricated microfluidic in vitro assays and intravital imaging of live murine lung to study the role of physical forces—including physical...
- The National Cancer Institute awarded Icahn School of Medicine at Mount Sinai $712,912 for research into the functional determinants of disseminated tumor cell dormancy in the brain under the Cancer Biology Research program (CFDA 93.396), effective August 1, 2026. The recipient will conduct a five-year project through July 31, 2031 to explore how breast cancer cells reshape the brain microenvironment to establish and maintain a dormancy-supportive niche. The research centers on the role of...
- The National Cancer Institute awarded Albert Einstein College of Medicine $680,121 on April 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate immune evasion mechanisms in basal-like breast cancer precancer stem cells and develop immunoprevention strategies to intercept progression to aggressive disease. The research focuses on understanding how precancer stem cells (pre-CSCs) generated through de-differentiation escape immune surveillance in basal-like breast...
- The National Institutes of Health National Cancer Institute awarded Albert Einstein College of Medicine $695,154 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate inter-individual phenotypes of cancer gene mutation susceptibility in the human airway. The award funds research defining how somatic mutations accumulate differently across individuals in lung cancer-relevant genes, with focus on early-stage driver mutations in normal bronchial...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded Albert Einstein College of Medicine $431,970 under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2026. The recipient will conduct research into epigenetic regulation of glioblastoma stem-like cells, specifically exploring how the arginine methyltransferase CARM1 controls NGFR and NTRK signaling pathways. The work encompasses two primary aims: testing...
- The National Cancer Institute, a division of the Department of Health and Human Services National Institutes of Health, awarded Health Research, Inc. (Roswell Park Division) $446,112 on July 3, 2026, under the Cancer Biology Research program (CFDA 93.396) to identify age-regulating breast cancer dormancy genes using C. elegans dauer models. The project investigates how chronological aging of dormant cancer cells drives metastatic relapse and reawakening after initial treatment. The recipient...
- The National Institutes of Health National Cancer Institute awarded Icahn School of Medicine at Mount Sinai $827,111 on July 21, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the role of the proline hydroxylase P4HA2 in metastatic tumor dormancy and the dormancy-to-reactivation transition. The project examines how dormant disseminated tumor cells regulate collagen extracellular matrix formation through control of proline hydroxylation, hypothesizing that P4HA2...